Advanced Filters
noise

Metastatic Cancer Clinical Trials

A listing of Metastatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,200 clinical trials

Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema

Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery …

18 - 75 years of age All Phase N/A
V Verity Teague

Shared Decision-making and Antimicrobial Stewardship in Secondary Care

To identify opportunities for antibiotic prescribing shared decision making between patients and prescribers in secondary care.

18 years of age All Phase N/A
C Constantin von zur Muehlen, MD

Radial Versus Femoral Secondary Access in Patients Undergoing TAVI

Severe symptomatic aortic stenosis (AS) with a high gradient is associated with a poor prognosis if not treated with valve replacement. Transcatheter aortic valve implantation has been shown in large randomized trials to be a safe and effective treatment option for patients at low, intermediate, or high risk. Transfemoral access …

18 years of age All Phase N/A
R Rita Mehta, MD

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

18 years of age All Phase 2
C Chi-Lu Chiang

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR) mutation. Generally, the efficacy of systemic treatment for LM is limited due to the …

20 years of age All Phase 2
F Fabrizio Di Benedetto, MD PhD FACS

LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis

This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM. Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life. …

18 - 77 years of age All Phase N/A

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the …

years of age All Phase N/A
J Jon Unosson

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy …

18 years of age All Phase N/A
H Hao Zheng, MD

Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma

This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical …

years of age All Phase N/A
Z Zhaohui Zhu

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

FAP is a fibroblast activation protein and overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-EB-FAPI--a new 177Lu therapeutic drug modified by Evans Blue (EB) for the first time in the world.

18 - 80 years of age All Phase 0

Simplify language using AI